Top Markets
Coin of the day
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
株式のランク #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
株価
$5.34
最終同期: 2026-08-14
時価総額
$2.59M
変化(1日)
-11.00%
変化(1年)
313.95%
US
取引 Jupiter Neurosciences, Inc. (JUNS)

カテゴリー

Jupiter Neurosciences, Inc.(JUNS)の配当利回りの履歴
Jupiter Neurosciences, Inc.(銘柄コード: JUNS)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Jupiter Neurosciences, Inc.(JUNS)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)